Biotech

All Articles

Pfizer takes $230M reached after axing stopped working DMD genetics therapy

.Pfizer's phase 3 Duchenne muscle dystrophy (DMD) gene therapy breakdown has gone a $230 thousand ho...

AC Immune finds 'landmark' prospective in Alzheimer's drug data

.After much more than 20 years of focus on neurodegenerative diseases, Swiss biotech air conditionin...

GSK goes down ph. 2 HPV vaccine over shortage of best-in-class potential

.GSK has actually scrapped a phase 2 individual papillomavirus (HPV) injection from its own pipeline...

OS Treatments refiles $6M IPO to money HER2 medication, preclinical ADCs

.Operating system Therapies will definitely provide on the NYSE American inventory swap this morning...

ALX's waning CD47 feedback fee sends out sell spiraling down

.ALX Oncology's period 2 stomach cancer feedback cost has actually deteriorated. After finding its o...

Ionis axes eye health condition from aim ats of Roche-partnered possibility after data disappoint

.Yet Another of Ionis Pharmaceuticals' key midphase readouts has actually fallen short of assumption...

Biogen's chief executive officer claimed no risky sell 2023. He's ready to be vibrant

.While Biogen's pharma peers are seeking for late-stage assets along with little bit of threat, chie...

Instil refills pipe in $2B biobucks manage ImmunOnco

.Instil Biography has actually been actually a biotech in search of a pipe after it junked its own l...

Biogen ignores Denali Alzheimer's collab

.Biogen has actually returned liberties to an early Alzheimer's illness plan to Denali Rehabs, leavi...

Takeda taps new head of US oncology company-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our summary of significant leadership hirings, shootings and...